scholarly journals Seroepidemiological Study of Epstein-Barr Virus in Patients with Head and Neck Tumors at Shahid Rajaee Hospital in Babolsar, Iran

2021 ◽  
Vol 7 (1) ◽  
Author(s):  
Dariush Moslemi ◽  
Ali Bijani ◽  
Amrollah Mostafazadeh ◽  
Hamid Safiri ◽  
Akram Mohammadi Nokhandani ◽  
...  
Keyword(s):  
Head And Neck ◽  
Epstein Barr Virus ◽  
Head And Neck Tumors ◽  
Enzyme Linked Immunosorbent Assay ◽  
Igg Antibodies ◽  
Carcinogenic Agent ◽  
Barr Virus ◽  
Neck Tumors ◽  
Number Of Patients ◽  
Epstein Barr

Background: Epstein-Barr virus (EBV) is a herpes virus, which is the cause of infectious mononucleosis. Seroepidemiological studies show that more than 95% of adults in the world are infected with this virus. This virus is a modifying virus that is associated with some malignancies such as Burkitt lymphoma, tumors in HIV-infected patients, Hodgkin's lymphoma, head and neck tumors, and T-cell lymphoma. Objectives: This study aimed to determine the prevalence of EBV and its relation to the type of cancer in patients with head and neck tumors, which were treated in the years 2015 to 2016 at Shahid Rajaee Radiation Hospital in Babolsar. Methods: During one year, all patients with head and neck tumors were monitored, and finally, a total of 37 patients who had pathologically confirmed diagnoses were entered into the study after obtaining written informed consent. In this descriptive study, specific anti-EBV viral capsid antigen (VCA) immunoglobulin M (IgM) and IgG antibodies were evaluated using enzyme-linked immunosorbent assay (ELISA). Also, other patients' information was obtained from their records. Results: The mean age of the patients was 59 years, and the number of men (70.23%) was higher than that of women (29.77%). Regarding the histopathology information and the frequency of tumors, most of the patients had squamous cell carcinoma (SCC) (73%) in the sites of the nasopharynx (27.02%) and pharynx (18.91%). The results of the ELISA test showed that IgG antibodies were positive in most of the patients (86.5 %). About the relation between the sites of the tumors and the IgG antibody, all patients (100%) with nasopharyngeal, tongue, and lips cancers were positive while they were the least in pharyngeal cancer (5.4%). Conclusions: This study showed that a significant number of patients with head and neck tumors (86.5%) were infected with this virus, which indicates that EBV as a carcinogenic agent in head and neck tumors has a high prevalence in our society and requires preventive and therapeutic actions.

scholarly journals ANTIBODY TO EPSTEIN-BARR VIRUS IN HEAD AND NECK TUMORS

1975 ◽  
Vol 78 (8) ◽  
pp. 729-737
Author(s):  
YUKIO INUYAMA ◽  
SHIGEJI SAITO ◽  
RAISUKE OZU ◽  
MASATOSHI HORIUCHI ◽  
KEI TAKASAKI ◽  
...  
Keyword(s):  
Head And Neck ◽  
Epstein Barr Virus ◽  
Head And Neck Tumors ◽  
Barr Virus ◽  
Neck Tumors ◽  
Epstein Barr

scholarly journals Detection of Epstein-Barr virus and human papillomavirus in head and neck tumors.

1993 ◽  
Vol 31 (1) ◽  
pp. 53-56 ◽  
Author(s):  
Y S Tyan ◽  
S T Liu ◽  
W R Ong ◽  
M L Chen ◽  
C H Shu ◽  
...  
Keyword(s):  
Human Papillomavirus ◽  
Head And Neck ◽  
Epstein Barr Virus ◽  
Head And Neck Tumors ◽  
Barr Virus ◽  
Neck Tumors ◽  
Epstein Barr

Enzyme-linked immunosorbent assay for IgG antibodies to Epstein-Barr virus-associated early antigens and viral capsid antigen

1984 ◽  
Vol 67 (2) ◽  
pp. 225-233 ◽  
Author(s):  
Gottfried Dölken ◽  
Ulrike Weitzmann ◽  
Carola Boldt ◽  
Michael Bitzer ◽  
Wolfram Brugger ◽  
...  
Keyword(s):  
Immunosorbent Assay ◽  
Epstein Barr Virus ◽  
Enzyme Linked Immunosorbent Assay ◽  
Viral Capsid ◽  
Viral Capsid Antigen ◽  
Igg Antibodies ◽  
Barr Virus ◽  
Epstein Barr

scholarly journals Evaluation of Four Commercial Systems for the Diagnosis of Epstein-Barr Virus Primary Infections

2010 ◽  
Vol 18 (3) ◽  
pp. 444-448 ◽  
Author(s):  
Fernando de Ory ◽  
María Eulalia Guisasola ◽  
Juan Carlos Sanz ◽  
Isabel García-Bermejo
Keyword(s):  
Primary Infection ◽  
Epstein Barr Virus ◽  
Nuclear Antigen ◽  
Enzyme Linked Immunosorbent Assay ◽  
Igg Antibodies ◽  
Past Infection ◽  
Recent Infection ◽  
Barr Virus ◽  
Epstein Barr ◽  
Virus Capsid Antigen

ABSTRACTTo compare the performance of four diagnostic commercial systems for Epstein-Barr virus (EBV) serology (for IgM and IgG virus capsid antigen [VCA] and EBV nuclear antigen [EBNA] antibodies), a collection of 125 samples from clinically suspected infectious mononucleosis cases was studied. Indirect immunofluorescence (IIF) for VCA IgM and IgG antibodies and anticomplement immunofluorescence for EBNA antibodies (Meridian Bioscience Inc.) were used as reference methods. By these methods, the cases were classified EBV primary infection (presence of IgM to VCA or IgG to VCA in the absence of EBNA antibodies;n= 82), EBV past infection (presence of VCA IgG and EBNA antibodies in the absence of VCA IgM;n= 26), or no infection (negative for the three markers;n= 17). The following systems were tested: two chemiluminescent immunoassays (CLIAs; the Liason [CLIA-L; DiaSorin] and the Immulite 2000 [CLIA-I; Siemens]), immunofiltration (IF; All.Diag), and an enzyme-linked immunosorbent assay (ELISA; DiaSorin). In the IgM assays, sensitivities ranged from 67.1% (ELISA) to 92.2% (CLIA-L) and specificities ranged from 93.8% (CLIA-L) to 100% (IF). In the VCA IgG assays, sensitivities varied from 79.4% (IF) to 94.4% (CLIA-I) and specificities varied from 94.4% (IF and CLIA-L) to 100% (CLIA-I and ELISA). In EBNA assays, sensitivities ranged from 78.1% (IF) to 93.8% (CLIA-I) and specificities ranged from 32.3% (CLIA-L) to 91.4% (IF). In relation to EBV profiles, the corresponding figures for sensitivity (in detecting primary infection) for IF, CLIA-L, CLIA-I, and ELISA were 92.7%, 93.8%, 89%, and 89.6%, respectively, and those for specificity (to exclude primary recent infection) were 90.7%, 94.6%, 97.7%, and 95.2%, respectively. Although there were limitations in some individual markers, especially CLIA-L for EBNA IgG, the systems evaluated appear to be useful for diagnosis of EBV infection.

scholarly journals Purified Hexameric Epstein-Barr Virus-Encoded BARF1 Protein for Measuring Anti-BARF1 Antibody Responses in Nasopharyngeal Carcinoma Patients

2010 ◽  
Vol 18 (2) ◽  
pp. 298-304 ◽  
Author(s):  
E. K. Hoebe ◽  
S. H. Hutajulu ◽  
J. van Beek ◽  
S. J. Stevens ◽  
D. K. Paramita ◽  
...  
Keyword(s):  
Nasopharyngeal Carcinoma ◽  
Epstein Barr Virus ◽  
Antibody Responses ◽  
Enzyme Linked Immunosorbent Assay ◽  
Humoral Immune ◽  
Barr Virus ◽  
Humoral Immune Responses ◽  
Human Sera ◽  
Epstein Barr ◽  
Humoral Responses

ABSTRACTWHO type III nasopharyngeal carcinoma (NPC) is highly prevalent in Indonesia and 100% associated with Epstein-Barr virus (EBV). NPC tumor cells express viral proteins, including BARF1, which is secreted and is considered to have oncogenic and immune-modulating properties. Recently, we found conserved mutations in the BARF1 gene in NPC isolates. This study describes the expression and purification of NPC-derived BARF1 and analyzes humoral immune responses against prototype BARF1 (B95-8) and purified native hexameric BARF1 in sera of Indonesian NPC patients (n= 155) compared to healthy EBV-positive (n= 56) and EBV-negative (n= 16) individuals. BARF1 (B95-8) expressed inEscherichia coliand baculovirus, as well as BARF1-derived peptides, did not react with IgG or IgA antibodies in NPC. Purified native hexameric BARF1 protein isolated from culture medium was used in enzyme-linked immunosorbent assay (ELISA) and revealed relatively weak IgG and IgA responses in human sera, although it had strong antibody responses to other EBV proteins. Higher IgG reactivity was found in NPC patients (P= 0.015) than in regional Indonesian controls or EBV-negative individuals (P< 0.001). IgA responses to native BARF1 were marginal. NPC sera with the highest IgG responses to hexameric BARF1 in ELISA showed detectable reactivity with denatured BARF1 by immunoblotting. In conclusion, BARF1 has low immunogenicity for humoral responses and requires native conformation for antibody binding. The presence of antibodies against native BARF1 in the blood of NPC patients provides evidence that the protein is expressed and secreted as a hexameric protein in NPC patients.

Enzyme-linked immunosorbent assay for the detection of Epstein-Barr Virus-Induced Antigens and antibodies

1983 ◽  
Vol 63 (2) ◽  
pp. 171-185 ◽  
Author(s):  
Lars Sternås ◽  
Janos Luka ◽  
Bengt Kallin ◽  
Anders Rosén ◽  
Werner Henle ◽  
...  
Keyword(s):  
Immunosorbent Assay ◽  
Epstein Barr Virus ◽  
Enzyme Linked Immunosorbent Assay ◽  
Barr Virus ◽  
Epstein Barr
Sign in / Sign up

Export Citation Format

Share Document